Literature DB >> 11581387

Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.

J D Lifson1, J L Rossio, M Piatak, T Parks, L Li, R Kiser, V Coalter, B Fisher, B M Flynn, S Czajak, V M Hirsch, K A Reimann, J E Schmitz, J Ghrayeb, N Bischofberger, M A Nowak, R C Desrosiers, D Wodarz.   

Abstract

Transient antiretroviral treatment with tenofovir, (R)-9-(2-phosphonylmethoxypropyl)adenine, begun shortly after inoculation of rhesus macaques with the highly pathogenic simian immunodeficiency virus (SIV) isolate SIVsmE660, facilitated the development of SIV-specific lymphoproliferative responses and sustained effective control of the infection following drug discontinuation. Animals that controlled plasma viremia following transient postinoculation treatment showed substantial resistance to subsequent intravenous rechallenge with homologous (SIVsmE660) and highly heterologous (SIVmac239) SIV isolates, up to more than 1 year later, despite the absence of measurable neutralizing antibody. In some instances, resistance to rechallenge was observed despite the absence of detectable SIV-specific binding antibody and in the face of SIV lymphoproliferative responses that were low or undetectable at the time of challenge. In vivo monoclonal antibody depletion experiments demonstrated a critical role for CD8(+) lymphocytes in the control of viral replication; plasma viremia rose by as much as five log units after depletion of CD8(+) cells and returned to predepletion levels (as low as <100 copy Eq/ml) as circulating CD8(+) cells were restored. The extent of host control of replication of highly pathogenic SIV strains and the level of resistance to heterologous rechallenge achieved following transient postinoculation treatment compared favorably to the results seen after SIVsmE660 and SIVmac239 challenge with many vaccine strategies. This impressive control of viral replication was observed despite comparatively modest measured immune responses, less than those often achieved with vaccination regimens. The results help establish the underlying feasibility of efforts to develop vaccines for the prevention of AIDS, although the exact nature of the protective host responses involved remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581387      PMCID: PMC114593          DOI: 10.1128/JVI.75.21.10187-10199.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Authors:  J L Rossio; M T Esser; K Suryanarayana; D K Schneider; J W Bess; G M Vasquez; T A Wiltrout; E Chertova; M K Grimes; Q Sattentau; L O Arthur; L E Henderson; J D Lifson
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

Review 3.  Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells.

Authors:  A J Zajac; K Murali-Krishna; J N Blattman; R Ahmed
Journal:  Curr Opin Immunol       Date:  1998-08       Impact factor: 7.486

4.  Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.

Authors:  C C Tsai; P Emau; K E Follis; T W Beck; R E Benveniste; N Bischofberger; J D Lifson; W R Morton
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 5.  Viral strategies of immune evasion.

Authors:  H L Ploegh
Journal:  Science       Date:  1998-04-10       Impact factor: 47.728

6.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

7.  Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation.

Authors:  R P Johnson; J D Lifson; S C Czajak; K S Cole; K H Manson; R Glickman; J Yang; D C Montefiori; R Montelaro; M S Wyand; R C Desrosiers
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 8.  Protective immunity induced by live attenuated simian immunodeficiency virus.

Authors:  R P Johnson; R C Desrosiers
Journal:  Curr Opin Immunol       Date:  1998-08       Impact factor: 7.486

9.  Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine.

Authors:  L O Arthur; J W Bess; E N Chertova; J L Rossio; M T Esser; R E Benveniste; L E Henderson; J D Lifson
Journal:  AIDS Res Hum Retroviruses       Date:  1998-10       Impact factor: 2.205

10.  Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

Authors:  X Jin; D E Bauer; S E Tuttleton; S Lewin; A Gettie; J Blanchard; C E Irwin; J T Safrit; J Mittler; L Weinberger; L G Kostrikis; L Zhang; A S Perelson; D D Ho
Journal:  J Exp Med       Date:  1999-03-15       Impact factor: 14.307

View more
  148 in total

1.  Efficient transmission and persistence of low-frequency SIVmac251 variants in CD8-depleted rhesus macaques with different neuropathology.

Authors:  Samantha L Strickland; Rebecca R Gray; Susanna L Lamers; Tricia H Burdo; Ellen Huenink; David J Nolan; Brian Nowlin; Xavier Alvarez; Cecily C Midkiff; Maureen M Goodenow; Kenneth Williams; Marco Salemi
Journal:  J Gen Virol       Date:  2012-02-01       Impact factor: 3.891

2.  Ex vivo analysis of SIV-infected cells by flow cytometry.

Authors:  Matthew R Reynolds; Shari M Piaskowski; Kimberly L Weisgrau; Andrea M Weiler; Thomas C Friedrich; Eva G Rakasz
Journal:  Cytometry A       Date:  2010-11       Impact factor: 4.355

3.  Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS.

Authors:  Kenneth Williams; Susan Westmoreland; Jane Greco; Eva Ratai; Margaret Lentz; Woong-Ki Kim; Robert A Fuller; John P Kim; Patrick Autissier; Prahbat K Sehgal; Raymond F Schinazi; Norbert Bischofberger; Michael Piatak; Jeffrey D Lifson; Eliezer Masliah; R Gilberto González
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

4.  Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.

Authors:  Donald N Forthal; Gary Landucci; Kelly Stefano Cole; Marta Marthas; Juan C Becerra; Koen Van Rompay
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication.

Authors:  Atze T Das; Bep Klaver; Alex Harwig; Monique Vink; Marcel Ooms; Mireille Centlivre; Ben Berkhout
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

6.  Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Authors:  John R Mascola; Mark G Lewis; Thomas C VanCott; Gabriela Stiegler; Hermann Katinger; Michael Seaman; Kristin Beaudry; Dan H Barouch; Birgit Korioth-Schmitz; Georgia Krivulka; Anna Sambor; Brent Welcher; Daniel C Douek; David C Montefiori; John W Shiver; Pascal Poignard; Dennis R Burton; Norman L Letvin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis.

Authors:  Juan T Borda; Xavier Alvarez; Ivanela Kondova; Pyone Aye; Meredith A Simon; Ronald C Desrosiers; Andrew A Lackner
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

8.  Elevated numbers of CD163+ macrophages in hearts of simian immunodeficiency virus-infected monkeys correlate with cardiac pathology and fibrosis.

Authors:  Joshua A Walker; Megan L Sulciner; Katherine D Nowicki; Andrew D Miller; Tricia H Burdo; Kenneth C Williams
Journal:  AIDS Res Hum Retroviruses       Date:  2014-03-11       Impact factor: 2.205

9.  Transcriptional profiling of experimental CD8(+) lymphocyte depletion in rhesus macaques infected with simian immunodeficiency virus SIVmac239.

Authors:  Steven E Bosinger; Simon P Jochems; Kathryn A Folkner; Timothy L Hayes; Nichole R Klatt; Guido Silvestri
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  Systemic dendritic cell mobilization associated with administration of FLT3 ligand to SIV- and SHIV-infected macaques.

Authors:  R Keith Reeves; Qing Wei; Jackie Stallworth; Patricia N Fultz
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.